Loading
A phase 3 trial of Moxetumomab pasudotox in Leukaemia, run by MedImmune LLC, completed.
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia is a phase 3 interventional study registered as NCT01829711 by MedImmune LLC, with 80 participants recorded, started 2013-04-29 and reaching its primary completion in 2017-05-24. Interventions recorded: Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox. Conditions recorded: Leukemia, Hairy Cell.
Linked to the drug Moxetumomab pasudotox because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
80 enrolled.
95% CI 25.8 to 47.8; Figures from the ClinicalTrials.gov results section (first posted 2018-08-27), not from a publication
Source95% CI 37.4 to 60.2; Figures from the ClinicalTrials.gov results section (first posted 2018-08-27), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Participants With Durable Complete Response (CR) Assessed by Blinded Independent Central Reviewprimary | Moxetumomab Pasudotox 40 µg/kg | 80 | 36.3% | - | - | link |
| Percentage of Participants With Durable CR by Investigator's Assessmentprimary | Moxetumomab Pasudotox 40 µg/kg | 80 | 48.8% | - | - | link |
Shares Moxetumomab pasudotox and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.
Shares Leukaemia (all types) and the tag pipeline.